ABSTRACT
BACKGROUND: Invasive mucormycosis (IM) is a rare invasive fungal infection with a high mortality rate. However, data concerning the clinical and economic burden of IM are scarce. AIM: To evaluate the direct treatment costs and additional expenditures of patients with IM. METHODS: A retrospective cost-of-illness analysis of cases with IM extracted from FungiScope - Global Registry for Emerging Fungal Infections, accessible through the epidemiological research platform www.ClinicalSurveys.net, was undertaken. Results of patients with IM were compared with those of matched patients with similar underlying conditions based on the German Diagnosis Related Group (G-DRG) coding. FINDINGS: Out of 46 patients with probable/proven IM, 31 (67%) patients were male and the median age was 53 years (range 11-88 years). Forty-two patients (92%) had haematological diseases as the most common risk factor. Analysis of cost factors identified antifungal treatment due to IM as the primary cost driver [22,816, 95% confidence interval (CI) 15,036-32,346], with mean overall direct treatment costs of 53,261 (95% CI 39,660-68,825). Compared with matched patients, patients with IM were treated in hospital for 26.5 additional days (standard deviation 31.8 days; P < 0.001), resulting in mean additional costs of 32,991 (95% CI 21,558-46,613; P < 0.001). Probable IM, as well as absence of chemotherapy, surgical measures due to IM, and antifungal prophylaxis were associated with lower overall costs. Nineteen patients (41.3%) died during hospitalization. CONCLUSION: This study demonstrates the considerable healthcare burden of IM. The choice of antifungal agent for treatment of IM had no impact on overall cost.
Subject(s)
Cost of Illness , Invasive Fungal Infections/economics , Invasive Fungal Infections/epidemiology , Mucormycosis/economics , Mucormycosis/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Antifungal Agents/economics , Antifungal Agents/therapeutic use , Child , Female , Hospitalization/economics , Humans , Invasive Fungal Infections/drug therapy , Male , Middle Aged , Mucormycosis/drug therapy , Retrospective Studies , Tertiary Care Centers , Young AdultABSTRACT
Infectious complications are a significant cause of morbidity and mortality in patients with malignancies specifically when receiving anticancer treatments. Prevention of infection through vaccines is an important aspect of clinical care of cancer patients. Immunocompromising effects of the underlying disease as well as of antineoplastic therapies need to be considered when devising vaccination strategies. This guideline provides clinical recommendations on vaccine use in cancer patients including autologous stem cell transplant recipients, while allogeneic stem cell transplantation is subject of a separate guideline. The document was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) by reviewing currently available data and applying evidence-based medicine criteria.
Subject(s)
Anti-Infective Agents/therapeutic use , Communicable Diseases/drug therapy , Hematologic Neoplasms/therapy , Neoplasms/therapy , Practice Guidelines as Topic/standards , Stem Cell Transplantation/adverse effects , Vaccination/standards , Communicable Diseases/etiology , Humans , PrognosisABSTRACT
Allogeneic hematopoietic cell transplantation is part of the standard of care for many hematological diseases. Over the last decades, significant advances in patient and donor selection, conditioning regimens as well as supportive care of patients undergoing allogeneic hematopoietic cell transplantation leading to improved overall survival have been made. In view of many new treatment options in cellular and molecular targeted therapies, the place of allogeneic transplantation in therapy concepts must be reviewed. Most aspects of hematopoietic cell transplantation are well standardized by national guidelines or laws as well as by certification labels such as FACT-JACIE. However, the requirements for the construction and layout of a unit treating patients during the acute phase of the transplantation procedure or at readmission for different complications are not well defined. In addition, the infrastructure of such a unit may be decisive for optimized care of these fragile patients. Here we describe the process of planning a transplant unit in order to open a discussion that could lead to more precise guidelines in the field of infrastructural requirements for hospitals caring for people with severe immunosuppression.
Subject(s)
Ambulatory Care Facilities/organization & administration , Facility Design and Construction , Hematopoietic Stem Cell Transplantation , Hospital Units/organization & administration , Accreditation/methods , Accreditation/organization & administration , Accreditation/standards , Ambulatory Care Facilities/standards , Certification , Facility Design and Construction/methods , Facility Design and Construction/standards , Health Services Needs and Demand/statistics & numerical data , Hematopoietic Stem Cell Transplantation/standards , Hematopoietic Stem Cell Transplantation/statistics & numerical data , Hospital Bed Capacity/standards , Hospital Bed Capacity/statistics & numerical data , Hospital Units/standards , Hospital Units/statistics & numerical data , Humans , Licensure, Hospital/organization & administration , Licensure, Hospital/standards , Practice Guidelines as Topic , Regenerative Medicine/organization & administration , Regenerative Medicine/standards , Regenerative Medicine/statistics & numerical data , Tissue and Organ Harvesting/methods , Tissue and Organ Harvesting/standards , Transfusion Medicine/organization & administration , Transfusion Medicine/standards , Transfusion Medicine/statistics & numerical data , Transplantation, Homologous/methods , Transplantation, Homologous/standardsABSTRACT
BACKGROUND: Serial chest CT is the standard of care to establish treatment success in invasive pulmonary aspergillosis (IPA). Data are lacking how response should be defined. METHODS: Digital CT images from a clinical trial on treatment of IPA were re-evaluated and compared with available biomarkers. Total volume of pneumonia was added up after manual measurement of each lesion, followed by statistical analysis. RESULTS: One-hundred and ninety CT scans and 309 follow-up datasets from 40 patients were available for analysis. Thirty-one were neutropenic. Baseline galactomannan (OR 4.06, 95%CI: 1.08-15.31) and lesion volume (OR 3.14, 95%CI: 0.73-13.52) were predictive of death. Lesion volume at d7 and trend between d7 and d14 were strong predictors of death (OR 20.01, 95%CI: 1.42-282.00 and OR 15.97, 95%CI: 1.62-157.32) and treatment being rated as unsuccessful (OR 4.75, 95%CI: 0.94-24.05 and OR 40.69, 95%CI: 2.55-649.03), which was confirmed by a Cox proportional hazards model using time-dependent covariates. CONCLUSION: Any increase in CT lesion volume between day 7 and day 14 was a sensitive marker of a lethal outcome (>50%), supporting a CT rescan each one and 2 weeks after initial detection of IPA. The predictive value exceeded all other biomarkers. Further CT follow-up after response at day 14 was of low additional value. KEY POINTS: ⢠CT evaluation offers good prediction of outcome for invasive pulmonary aspergillosis. ⢠Predictive capability exceeds galactomannan, blood counts, and lesion count. ⢠Any progression between day 7 and day 14 constitutes a high-risk scenario.
Subject(s)
Invasive Pulmonary Aspergillosis/diagnostic imaging , Tomography, X-Ray Computed/methods , Adult , Aged , Disease Progression , Female , Galactose/analogs & derivatives , Humans , Image Interpretation, Computer-Assisted , Invasive Pulmonary Aspergillosis/mortality , Male , Mannans/metabolism , Middle Aged , Pneumonia/diagnostic imaging , Predictive Value of Tests , Survival Analysis , Tomography, X-Ray Computed/statistics & numerical dataABSTRACT
Infections of the central nervous system (CNS) are infrequently diagnosed in immunocompetent patients, but they do occur in a significant proportion of patients with hematological disorders. In particular, patients undergoing allogeneic hematopoietic stem-cell transplantation carry a high risk for CNS infections of up to 15%. Fungi and Toxoplasma gondii are the predominant causative agents. The diagnosis of CNS infections is based on neuroimaging, cerebrospinal fluid examination and biopsy of suspicious lesions in selected patients. However, identification of CNS infections in immunocompromised patients could represent a major challenge since metabolic disturbances, side-effects of antineoplastic or immunosuppressive drugs and CNS involvement of the underlying hematological disorder may mimic symptoms of a CNS infection. The prognosis of CNS infections is generally poor in these patients, albeit the introduction of novel substances (e.g. voriconazole) has improved the outcome in distinct patient subgroups. This guideline has been developed by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) with the contribution of a panel of 14 experts certified in internal medicine, hematology/oncology, infectious diseases, intensive care, neurology and neuroradiology. Grades of recommendation and levels of evidence were categorized by using novel criteria, as recently published by the European Society of Clinical Microbiology and Infectious Diseases.
Subject(s)
Central Nervous System/physiopathology , Communicable Diseases/physiopathology , Hematologic Diseases/microbiology , Hematopoietic Stem Cell Transplantation/adverse effects , Central Nervous System/microbiology , Communicable Diseases/diagnosis , Communicable Diseases/drug therapy , Communicable Diseases/microbiology , Germany/epidemiology , Guidelines as Topic , Hematologic Diseases/drug therapy , Hematologic Diseases/epidemiology , Hematologic Diseases/physiopathology , Hematology , Humans , Medical Oncology , Toxoplasma/pathogenicity , Voriconazole/therapeutic useABSTRACT
Non-relapse mortality after Allo-SCT has significantly decreased over the last years. Nevertheless, relapse remains a major cause for post SCT mortality in patients with AML and high-risk myelodysplastic syndrome (MDS). In this retrospective single-center analysis, we have analyzed the treatment outcomes of 108 patients with AML or MDS, who relapsed after Allo-SCT. Seventy of these patients (65%) were treated with salvage therapies containing chemotherapy alone, allogeneic cell-based treatment or the combination of both. Thirty-eight patients (35%) received palliative treatment. Median OS after diagnosis of relapse was 130 days. Compared with patients who received chemotherapy alone, response to salvage therapy was significantly improved in patients treated with a combination of chemo- and allogeneic cell-based therapy (CR rate 57% vs 13%, P=0.002). Among risk factors concerning pretreatment characteristics, disease status before first Allo-SCT, and details of transplantation, only the time interval from Allo-SCT to relapse was an independent predictor of response to salvage therapy and OS. These data confirmed that time to relapse after transplantation is an important prognostic factor. Up to now, only patients eligible for treatment regimens containing allogeneic cell-based interventions achieved relevant response rates.
Subject(s)
Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/therapy , Myelodysplastic Syndromes/mortality , Myelodysplastic Syndromes/therapy , Salvage Therapy , Adolescent , Adult , Aged , Allografts , Disease-Free Survival , Female , Humans , Male , Middle Aged , Recurrence , Retrospective Studies , Survival Rate , Time FactorsSubject(s)
Oncogene Proteins, Fusion/genetics , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fatal Outcome , Hematopoietic Stem Cell Transplantation , Humans , Male , Mutation , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Transplantation, Homologous , Young AdultABSTRACT
After allo-SCT, analysis of CD34(+) lineage-specific donor cell chimerism (DCC) is a sensitive method for monitoring minimal residual disease in patients with AML or myelodysplastic syndrome (MDS) with CD34 expression. To substantiate evidence of whether immune interventions in patients with impending relapse, defined by incomplete lineage-specific DCC, may prevent hematological relapse, we performed a retrospective nested case control study. Unsorted and lineage-specific DCC were measured in 134 patients. Forty-three patients had an incomplete CD34(+)-DCC with no other evidence of relapse. After immediate tapering of immunosuppressive treatment (30 patients) and/or infusion of donor lymphocytes (10 patients), 21 patients remained in remission (conversion to complete lineage-specific DCC) and 22 relapsed. Relapse-free survival at 3 years of the 91 patients with stable DCC and of the 43 patients with incomplete DCC was 74% (95% confidence interval (CI), 64-83%) and 40% (95% CI, 24-58%), respectively. OS rates were 79% (95% CI, 70-88%) and 52% (95% CI, 35-69%), respectively. These results, with 49% of patients with impending relapse successfully treated with immune intervention, highly suggest that analysis of CD34(+)-DCC is an important tool for monitoring and the management of AML and MDS patients after allo-SCT.
Subject(s)
Antigens, CD34/immunology , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cells/immunology , Leukemia, Myeloid, Acute/surgery , Myelodysplastic Syndromes/surgery , Adolescent , Adult , Aged , Case-Control Studies , Chimerism , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukemia, Myeloid, Acute/immunology , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Recurrence , Retrospective Studies , Transplantation Chimera , Transplantation, Homologous , Young AdultABSTRACT
Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade ≥ 4 in 2 of 8 patients or ≥ 3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics were linear across the investigated dosages and followed a two-compartment model, with weight as the covariate on clearance and sex as the covariate on central volume of distribution. Simulated peak plasma concentrations at steady state ranged from 14.2 to 40.6 mg/liter (28%), trough concentrations from 4.1 to 11.8 mg/liter (58%), and area under the concentration-time curve from 175 to 500 mg/liter/h (32%) (geometric mean, geometric coefficient of variation). Treatment was well tolerated without dose-limiting toxicity. The rate of complete or partial responses was 54.3%, and the overall mortality at 12-week follow-up was 28.3%. In first-line treatment of invasive aspergillosis, daily doses of up to 200 mg caspofungin were well tolerated and the maximum tolerated dose was not reached. Pharmacokinetics was linear. Response rates were similar to those previously reported for voriconazole and liposomal amphotericin.
Subject(s)
Antifungal Agents/adverse effects , Antifungal Agents/pharmacokinetics , Aspergillosis/drug therapy , Echinocandins/adverse effects , Echinocandins/pharmacokinetics , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Aspergillosis/microbiology , Aspergillosis/mortality , Caspofungin , Cohort Studies , Dose-Response Relationship, Drug , Drug Administration Schedule , Echinocandins/administration & dosage , Female , Follow-Up Studies , Humans , Lipopeptides , Male , Middle Aged , Survival Analysis , Treatment OutcomeSubject(s)
CCAAT-Enhancer-Binding Protein-alpha/genetics , Germ-Line Mutation , Hematopoietic Stem Cells/metabolism , Leukemia, Myeloid, Acute/surgery , Neoplastic Syndromes, Hereditary/genetics , Peripheral Blood Stem Cell Transplantation , Adult , Anticipation, Genetic , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child, Preschool , Combined Modality Therapy , Female , Hematopoietic Stem Cells/pathology , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/genetics , Neoplasms, Second Primary/genetics , Neoplasms, Second Primary/surgery , Pedigree , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Recurrence , Salvage Therapy , Survivors , Transplantation, HomologousABSTRACT
BACKGROUND: Invasive zygomycosis accounts for a significant proportion of all invasive fungal diseases (IFD), but clinical data on the clinical course and treatment response are limited. PATIENTS AND METHODS: Fungiscope-A Global Rare Fungal Infection Registry is an international university-based case registry that collects data of patients with rare IFD, using a web-based electronic case form at www.fungiscope.net. RESULTS: Forty-one patients with invasive zygomycosis from central Europe and Asia were registered. The most common underlying conditions were malignancies (n = 26; 63.4%), diabetes mellitus (n = 7; 17.1%) and solid organ transplantation (n = 4; 9.8%). Diagnosis was made by culture in 28 patients (68.3%) and by histology in 26 patients (63.4%). The main sites of infection were the lungs (n = 24; 58.5%), soft tissues (n = 8; 19.5%), rhino-sinu-orbital region (n = 8; 19.5%) and brain (n = 6; 14.6%). Disseminated infection of more than one non-contiguous site was seen in six patients (14.6%). Mycocladus corymbifer was the most frequently identified species (n = 10, 24.4%). A favourable response was observed in 23 patients (56.1%). Overall survival was 51.2% (n = 21). At diagnosis, four patients (9.8%) were on continuous antifungal prophylaxis with itraconazole (n = 1; 2.4%) or posaconazole (n = 3; 7.3%). Initial targeted treatment with activity against zygomycetes was administered to 34 patients (82.9%). Liposomal amphotericin B was associated with improved response (P = 0.012) and survival rates (P = 0.004). CONCLUSIONS: Pathogen distribution and, consequently, drug susceptibility seem to vary across different geographic regions. Furthermore, protection from invasive zygomycosis for patients on posaconazole prophylaxis is not absolute. Our findings indicate that the use of liposomal amphotericin B as first-line treatment for patients diagnosed with zygomycoses merits further investigation, preferably in the form of a clinical trial.
Subject(s)
Mucorales/isolation & purification , Zygomycosis/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Asia/epidemiology , Child , Child, Preschool , Databases, Factual , Diabetes Complications , Europe/epidemiology , Female , Humans , Immunocompromised Host , Male , Middle Aged , Neoplasms/complications , Organ Transplantation/adverse effects , Survival Analysis , Treatment Outcome , Young Adult , Zygomycosis/drug therapy , Zygomycosis/pathology , Zygomycosis/physiopathologyABSTRACT
Despite antibiotics, antifungals and haematopoietic growth factors, infections remain a major threat to neutropenic patients. To determine the role of granulocyte transfusions (GTs) in anti-infective therapy during neutropenia, GT administration was randomized in 74 adults with haematological or malignant diseases, febrile neutropenia and pulmonary or soft-tissue infiltrates after conventional or high-dose chemotherapy, a majority of them after allo-SCT (n=39). Neutrophil reconstitution was equal in the treatment and control arm. GT toxicity was minimal. The probability of 28-day survival after randomization was >80% in both groups, and no effect of GT on survival until day 100 could be detected in patients with fungal (n=55), bacterial or unknown infection (n=17) and various levels of neutropenia (ANC <500 vs >500 x 10(6)/l). These findings can be attributed primarily to procedural obstacles, such as long delay from randomization to first GT, low cell content and slow sequence of GT, difficulties in randomizing a safe and potentially life-saving treatment in severely endangered individuals, and a large proportion of rapidly recovering patients in both arms. The requirement of another trial in a more specific patient population with daily transfusions of sufficient numbers of granulocytes to support or refute the empirically acknowledged benefits of GT is discussed.
Subject(s)
Granulocytes/transplantation , Leukocyte Transfusion , Neutropenia/therapy , Adolescent , Adult , Aged , Female , Hematologic Diseases/complications , Hematologic Diseases/therapy , Humans , Infections/mortality , Infections/therapy , Male , Middle Aged , Neoplasms/complications , Neoplasms/therapy , Neutropenia/mortality , Survival Rate , Treatment Outcome , Young AdultABSTRACT
BACKGROUND: The aim of the study was to compare the efficacy of empirical antifungals in combination with broad spectrum antibiotics with that of antibiotics alone in high risk febrile neutropenic cancer patients not responding to initial antibacterial therapy. PATIENTS AND METHODS: A prospective, randomized controlled trial was conducted at 22 cancer centers in Germany. Patients with fever of unknown origin were randomized to either piperacillin (Pip) plus an aminoglycoside (AMG) (arm A) or a third generation cephalosporin (Ceph) plus AMG (arm B). Patients not responding after 4-6 days were randomized to either imipenem (Imi) plus glycopeptide (GLP) (arm C), or Imi/GLP plus amphotericin B deoxycholate (AmB) plus 5-flucytosine (5-FC) (arm D), or Imi/GLP plus fluconazole (Fluco) (arm E). A successful outcome was defined as resolution of fever. RESULTS: In arm A, 192 of 373 patients (51.5%) responded as compared to 176 of 344 patients (51.2%) in arm B. The response rates of 155 patients randomized for further empirical treatment were 55.6%, 77.8% and 62.5% in arm C, D and E, respectively. The difference between arm C and D was of borderline statistical significance (p = 0.06) after correction for multiple testing. CONCLUSION: In neutropenic cancer patients with persistent fever the combination of antibiotics with AmB/5-FC is superior to salvage antibacterial therapy alone. There is no difference in efficacy between Pip and third generation Ceph given as initial empirical therapy in combination with an AMG.
Subject(s)
Antifungal Agents/therapeutic use , Fever of Unknown Origin/etiology , Neoplasms/complications , Neutropenia/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Neutropenia/etiology , Prospective StudiesABSTRACT
BACKGROUND: Caspofungin has shown efficacy in empirical antifungal therapy in neutropenic patients, refractory invasive Aspergillus infections and invasive candidiasis. Here we report the currently largest series of patients treated with caspofungin outside clinical trials. METHODS: Centres in Germany that were known to treat patients with invasive fungal infections were asked to fill out detailed questionnaires for all patients treated with caspofungin. No effort was made to influence the decision to use caspofungin. RESULTS: A total of 118 patients were evaluable (median age 48 years, interquartile range 38-58), out of which 41 (35%) suffered from acute leukaemia, 31 (26%) had allogeneic stem cell transplants, 16 (14%) lymphoma or myeloma, 8 (7%) autologous stem cell transplants and 22 (19%) other causes for immunosuppression. One hundred and six patients were evaluable for efficacy out of which 68 (64%) patients achieved a complete or partial remission. A total of 81 out of 115 (70%) patients were alive 30 days after the end of caspofungin therapy. Response rates were similar in proven (20/32, 63%) and probable (27/46, 59%) infections, in neutropenic patients (41/55, 75%) and in patients who were (44/70, 63%) or were not (24/36, 67%) refractory to antifungal pre-treatment. The response rate in mechanically ventilated patients was 29% (7/24). Caspofungin was well tolerated, even in 14 patients, who were concomitantly treated with ciclosporin A, no drug-related elevations of bilirubin, alanine aminotransferase or creatinine were found. CONCLUSIONS: This open case study of severely ill patients with invasive fungal infections demonstrates both excellent efficacy and very low toxicity of caspofungin.
Subject(s)
Antifungal Agents/therapeutic use , Immunocompromised Host , Mycoses/drug therapy , Peptides, Cyclic/therapeutic use , Adult , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects , Caspofungin , Critical Illness , Echinocandins , Female , Germany , Humans , Lipopeptides , Male , Middle Aged , Mycoses/immunology , Mycoses/mortality , Peptides, Cyclic/administration & dosage , Peptides, Cyclic/adverse effects , Prospective Studies , Retrospective Studies , Treatment OutcomeABSTRACT
Antimicrobial agents are among the most frequently prescribed therapeutics in the supportive care of children and adolescents with cancer or following hematopoietic stem cell transplantation. Most of these agents are cleared from the body by elimination of unchanged drug by the kidney and/or metabolism by the liver. Impaired renal and hepatic function may have profound effects on the pharmacokinetics and pharmacodynamics of antimicrobial agents, necessitating modification of the dosage regimen in order to avoid toxicity through accumulation of the parent and/or its metabolites. Key to minimize such toxicities is a thorough understanding of the antimicrobial drug armamentarium and a careful evaluation of benefits and risks of antimicrobial interventions. This article reviews the mechanisms of renal and hepatic drug clearance in the normal state and in the state of functional impairment, their implications for antimicrobial therapy and dosage recommendations for pediatric cancer patients with impaired renal or hepatic function.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/pharmacokinetics , Antifungal Agents/therapeutic use , Antiviral Agents/pharmacokinetics , Antiviral Agents/therapeutic use , Liver Failure/complications , Neoplasms/therapy , Opportunistic Infections/drug therapy , Renal Insufficiency/complications , Adolescent , Anti-Bacterial Agents/adverse effects , Antifungal Agents/adverse effects , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Antiviral Agents/adverse effects , Child , Hematopoietic Stem Cell Transplantation , Humans , Kidney Function Tests , Liver Failure/blood , Liver Function Tests , Metabolic Clearance Rate/physiology , Neoplasms/immunology , Neutropenia/complications , Neutropenia/etiology , Opportunistic Infections/blood , Renal Insufficiency/bloodABSTRACT
Patients undergoing allogeneic stem cell transplantation are at high risk for infection with a variety of pathogens during different phases of the procedure. Bacteria and fungi predominate the first phase until engraftment. During the second phase, from engraftment to about day 100, major infectious problems are caused by fungi and cytomegalovirus. Both pathogens remain important under continued immunosuppression, however, in the late post-transplantation period infections with encapsulated bacteria may become a problem. In this review the Infectious Diseases Working Party of the DGHO gives recommendations for prophylaxis of infections under allogeneic stem cell transplantation with drugs and other measures. The aim of the group was to do this on an evidence-based-medicine rating, if possible.
Subject(s)
Anti-Infective Agents/therapeutic use , Antibiotic Prophylaxis , Bone Marrow Transplantation , Infection Control/methods , Humans , Preventive Medicine , Transplantation, HomologousSubject(s)
Bone Marrow Transplantation , Leukemia, Myeloid/therapy , Neoplasm Recurrence, Local/diagnosis , Neoplasm, Residual/diagnosis , Acute Disease , Adult , Aged , Antigens, CD34/metabolism , Chimerism , Female , Hematopoiesis , Humans , Leukemia, Myeloid/classification , Leukemia, Myeloid/immunology , Living Donors , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Transplantation, HomologousABSTRACT
Conventional medical curricula present information pertinent to chronic inflammatory diseases, infectious diseases and transplantation, via systematic lectures and courses in medical specialties without any integrated approach. The authors report on a 3-week model course that attempts to provide students with an overview of clinical presentation, diagnostics, and therapy of representative disease entities with particular emphasis on the interdisciplinary approach to these problems in hospital practice. In addition to problem-based learning in small groups, the model course comprises interdisciplinary concept lectures, practical demonstrations of specific diagnostic procedures, and bedside teaching. In the meantime, the course "Problem-Based Learning--Inflammation and Transplantation" has been held twice successfully as a mandatory course in the clinical part of the curriculum at the Muenster Medical School.
Subject(s)
Autoimmune Diseases , Communicable Diseases , Education, Medical/trends , Inflammation , Problem-Based Learning/trends , Transplantation/education , Curriculum/trends , Forecasting , Germany , Humans , Models, EducationalABSTRACT
Now that modern medicine can provide increasing chances of cure to patients with formerly incurable disorders, therapy-related complications play the key role in outcome. Thus, among opportunistic infections, severe candidiasis remains a challenge. A multidisciplinary panel of 20 investigators was formed to find a consensus on antifungal strategies for various underlying conditions in neutropenic and non-neutropenic patients. To record their preferences, the investigators used an anonymous voting system. Among antifungal agents, fluconazole emerged as the major alternative to the classic amphotericin B, being therapeutically at least equivalent but clearly less toxic. Factors that restrict the use of fluconazole include pretreatment with azoles, involvement of resistant species like Candida krusei, and an inability to exclude aspergillosis. Flucytosine can be reasonably combined with both amphotericin B and fluconazole. Within the limited antifungal armamentarium, amphotericin B lipid formulations and itraconazole also appear useful and require further investigation. The general consensus of the group is that antifungal agents should be administered at sufficient dosages, rather early, and often empirically.